Literature DB >> 34168467

Geographic Differences on Clinical Manifestations of COVID-19 Infection Between Overseas Chinese and Local Chinese Patients.

Yanhua Liang1, Shanglong Kou1,2, Xiaohe Li1, Zhiyi Ke1, Rongrong Zou1, Yanchao Pan1,3, Jing Yuan1.   

Abstract

INTRODUCTION: The novel coronavirus (COVID-19) has become a global pandemic with sharp rises in the number of confirmed cases and rapid spread across the world. Here, we looked at the effects of geographic differences on clinical manifestations of SARS-CoV-2 infected patients.
METHODS: A total of 114 confirmed COVID-19 patients were included in this study. The epidemiological, demographic, clinical, as well as laboratory findings were extracted from the electronic medical records of these patients.
RESULTS: We report the observation that patients from overseas residents diagnosed with COVID-19 were mildly symptomatic with cough and presented with lower inflammatory response and attenuated virus clearance rate, as well as correspondingly prolonged days of hospital stay than local Chinese patients. Moreover, the receiver-operating characteristic (ROC) analysis, performed to provide a measure of the difference between two groups, showed that serum albumin had the highest area under the curve value (0.81, p < 0.001). DISCUSSION: Our results suggested that blood albumin level acted as a predictive value in distinguishing clinical features between local and overseas Chinese. This work underscores the need to identify distinguishably prognostic factors of geographical dissimilarity in COVID-19 patients.
© 2021 Liang et al.

Entities:  

Keywords:  COVID-19 patients; clinical manifestations; geographic differences; inflammatory responses

Year:  2021        PMID: 34168467      PMCID: PMC8216746          DOI: 10.2147/IDR.S307238

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.003


Introduction

Since 30 January 2020, the coronavirus disease COVID-19 has been announced as a global public health emergency with almost 100 million confirmed infected cases and rising up to millions of deaths. Travel-related SARS-CoV-2 transmission has been demonstrated to promote the global prevalence of COVID-19 and affect the epidemic trajectory in the community.1,2 Many countries shut down all their external borders and implemented massive travel restrictions in attempts to mitigate the spreading of the COVID-19 pandemic.2,3 Some studies revealed the regional and country-wide mortality differences in communities.4–6 Here we looked at the effect of geographic difference on clinical manifestations of SARS-CoV-2 infected patients by comparison of overseas Chinese and local Chinese.

Materials and Methods

Coronavirus (2019-nCoV) RNA Detection Kit (PCR Fluorescence probing) approved by China’s National Medical Products Administration, was used for SARS-CoV-2 virus testing. Conditions for the amplifications include reverse transcription at 50°C for 15 min, pre-denaturation at 95°C for 15 min, followed by 45 cycles of 94°C for 15 s and 55°C for 45 s for fluorescence detection. The receiver operating characteristic curve analysis was used to determine the optimal threshold cut-off value. A cycle threshold (Ct) value ≤40 was defined as a positive test. Demographic and clinical data of involved patients were derived from electronic medical records. Routine blood tests were performed by Sysmex XT-2000i automated hematology analyzer (Sysmex Corporation). Inflammatory biomarker assays were run on ARCHITECT i2000 SR analyzer (Abbott Diagnostics) according to the protocols recommended by the manufacturer. This study was conducted in accordance with the Declaration of Helsinki. The study was approved by Shenzhen Third People’s Hospital Ethics Committee and the written informed consent was waived by the Ethics Commission. Any data we collected and analysed in this retrospective study were derived from clinical raw records without any intervention or influence on clinical treatment. No additional collection of human samples or genetic resource materials was performed in our study. All methods were carried out in accordance with relevant guidelines and regulations. To fully protect the privacies and rights of patients, only clinical data observations were used for publication and personal information will not be disclosed to any third party without patient’s consent. The Receiver Operating Characteristic (ROC) curve analysis was carried out to explore and compare the performance of haematological parameters. The area under the curve was calculated to assess the capability of each parameter on discriminating the differences between different comparisons. Mean (± standard deviation [SD]) and range were reported for normally distributed, continuous variables. One-way ANOVA was used to compare continuous variables among three groups, while the post hoc test was applied with Tukey’s method. All statistical tests were 2-tailed, and a p value less than 0.05 was considered statistically significant.

Results

Enrolled from February 6 to April 62020, a total of 114 patients with confirmed COVID-19 by RT-PCR swab test, as previously described,7 were transferred to Shenzhen Third People’s Hospital for medical isolation and treatment. Of the total, 50 of them were incoming passengers, including 40 Chinese overseas residents and students, as well as 10 foreigners, found to be SARS-CoV-2-positive during the two-week quarantine in place for arrivals in China. They were predominately from Western Europe (n = 30, 60%) and North America (n = 13, 26%), followed by South East Asia (n = 5, 10%), as well as Eastern Europe (n = 2, 4%). Twelve of them had a contact history with suspected cases of symptomatic individuals. Another 64 patients were local Chinese residents and 45 of them had a recent travel history to Hubei Province. Additionally, 72% of the travelers presented initial signs and symptoms within 3 days and 17 of them presented with fever or cough once they arrived. The local patients, mostly with fever (n = 37, 57.81%), were admitted to hospital with a median of 3 days (IQR: 1.25–6.39) since symptom onset. Statistical significances were identified on frequencies of cough (ANOVA, p <0.001) and phlegm (ANOVA, p =0.033) among participants, with more than three-fold of overseas Chinese patients having moderate or severe cough in comparison with local Chinese patients (as shown in Tables 1, 50.00% vs 15.63%, p <0.001 for Tukey’s post-hoc test).
Table 1

Baseline Characteristics of 114 COVID-19 Patients

Overseas Group, N=50Local Chinese Group, N=64p value
One-Way ANOVATukey’s Post-Hoc Test
Foreign Travelers, N=10Overseas Chinese, N=40Foreigner vs Overseas ChineseForeigner vs LocalOverseas vs Local
Age (median, IQR)32.5(18.0–38.5)22(19.0–30.3)37.5(28.0–51.0)<0.0010.8190.162<0.001
Sex (Number, Percentage)
Male770.00%2357.50%3351.56%0.3730.7610.5270.827
Female330.00%1742.50%3148.44%
Definite contact history440.00%820.00%4570.31%<0.0010.731<0.001<0.001
Comorbidities110.00%820.00%1015.63%0.7380.7340.8990.833
Initial signs and symptoms
Fever48.00%1947.50%3757.81%0.3750.9060.5180.511
Cough36.00%2050.00%1015.63%<0.0010.2960.159<0.001
Phlegm00.00%1025.00%69.38%0.0330.1010.6990.064
Admission DaysLaboratory parameters (mean+SD, 95% CI)
Day 1–3Lymphocyte (109/L)2.27±2.01(1.97–4.37)1.81±0.61(1.51–2.16)1.76±0.89(1.20–1.97)0.2800.3490.2500.962
WBC (109/L)5.50±1.71(3.79–7.00)5.10±1.54(4.30–5.12)5.30±1.78(4.07–5.57)0.7520.7830.9330.837
Platelet (109/L)223.90±44.03(178.76–260.48)218.88±55.62(194.56–234.68)216.93±67.19(180.19–220.41)0.9430.9710.9410.987
ALB (g/L)44.43±2.09(43.79–46.51)46.89±3.16(45.88–48.07)43.39±2.87(41.90–43.84)<0.0010.0500.552<0.001
CRP (mg/L)3.63±4.58(0.39–8.46)5.92±9.80(2.75–9.92)14.80±21.68(11.47–32.26)0.0220.9940.1470.039
IL-6 (pg/mL)3.84±2.42(2.12–6.15)4.50±4.15(3.32–6.31)8.36±7.81(6.03–12.31)0.0120.9530.1110.017
PCT(ng/mL)0.049±0.030(0.019–0.091)0.041±0.042(0.025–0.064)0.096±0.283(0.020–0.173)0.4200.9940.7850.411
Day 4–8Lymphocyte (109/L)2.13±1.31(0.21–4.60)2.06±0.49(1.89–2.37)1.78±0.80(1.07–2.18)0.1790.9710.4290.220
WBC (109/L)5.21±0.95(3.79–6.30)5.40±2.17(3.98–5.16)5.93±2.68(4.56–8.73)0.5010.9740.6790.566
Platelet (109/L)220.22±67.52(188.58–293.17)234.92±69.92(211.61–258.23)265.40±73.42(225.68–314.46)0.0720.8450.1970.131
ALB (g/L)44.26±2.60(43.92–46.31)43.06±3.17(33.70–49.50)42.01±3.48(40.17–43.94)0.1220.9870.5130.270
CRP (mg/L)5.39±10.36(0.98–9.71)6.19±12.39(1.47–10.90)12.06±17.38(6.84–17.28)0.2070.9910.4930.244
IL-6 (pg/mL)2.76±2.25(0.68–4.85)5.32±8.94(1.45–9.18)7.91±11.32(2.76–13.07)0.4180.8090.4360.641
PCT (ng/mL)0.024±0.006(0.019–0.028)0.106±0.38(0.001–0.258)0.052±0.104(0.022–0.082)0.5080.6060.9350.575
Day 9–15Lymphocyte (109/L)2.00±0.43(1.68–2.72)1.96±0.60(1.77–2.29)1.97±0.89(1.40–2.07)0.9940.9930.9940.999
WBC (109/L)6.26±1.93(3.77–9.44)6.00±2.05(4.97–6.23)6.26±1.75(5.58–7.60)0.8170.9340.9990.807
Platelet (109/L)240.88±62.55(219.00–275.27)245.90±48.91(229.42–271.88)289.43±75.35(275.02–325.82)0.0080.9810.1420.015
ALB (g/L)43.76±2.73(41.48–46.04)43.10±2.60(42.07–44.13)41.46±3.35(39.29–42.69)0.0270.8570.1270.066
CRP (mg/L)1.30±1.01(−13.99–39.08)3.27±4.92(1.19–2.73)5.25±6.58(2.91–10.17)0.1220.6850.1810.346
IL-6 (pg/mL)3.30±2.61(0.89–5.71)2.74±1.54(1.98–3.51)4.46±2.65(3.61–6.01)0.0490.8540.4660.043
PCT (ng/mL)0.025±0.009(0.018–0.033)0.044±0.049(0.010–0.059)0.037±0.027(0.022–0.044)0.4260.3950.6130.767
Day 16–22Lymphocyte (109/L)3.52±2.44(2.06–6.54)2.03±0.59(1.71–2.36)1.75±0.38(1.52–1.93)0.0030.0120.0020.674
WBC (109/L)6.74±2.28(3.91–9.57)6.25±1.38(5.48–7.02)6.11±1.30(5.42–6.88)0.7030.7960.6790.962
Platelet (109/L)238.20±91.01(125.19–351.21)236.67±55.09(180.49–300.51)263.33±58.02(234.48–292.19)0.4310.9990.7010.439
ALB (g/L)44.98±2.49(41.89–48.07)43.01±2.23(41.13–44.32)40.91±2.50(39.01–44.02)0.0040.2620.0060.051
CRP (mg/L)0.31±0.37(−0.15–0.77)4.38±4.43(0.37–3.55)5.15±7.38(1.35–8.94)0.1930.1740.2710.894
IL-6 (pg/mL)1.50±0.30(1.48–1.54)2.19±0.77(−1.98–12.37)3.43±1.86(2.10–4.76)0.0750.7480.1190.117
PCT (ng/mL)0.022±0.003(0.018–0.026)0.041±0.030(0.022–0.061)0.016±0.020(0.007–0.025)0.0110.2450.8590.008
Length of hospital stay (mean (day); (95% CI))26.9±7.0(21.9–31.9)26.4±8.8(23.6–29.2)15.6±2.8(14.9–16.3)<0.0010.973<0.001<0.001

Notes: Data are given as counts with percentage, mean ± SD with 95% CI, or median with range; for data not normally distributed, median with interquartile range (IQR) is used. Categorical variables are given as counts and percentages. Determined using one-way analysis of variance and p values in bold are considered to be significant.

Abbreviations: ALB, Albumin; CRP, C-reactive protein; IL-6, Interleukin-6; PCT, procalcitonin.

Baseline Characteristics of 114 COVID-19 Patients Notes: Data are given as counts with percentage, mean ± SD with 95% CI, or median with range; for data not normally distributed, median with interquartile range (IQR) is used. Categorical variables are given as counts and percentages. Determined using one-way analysis of variance and p values in bold are considered to be significant. Abbreviations: ALB, Albumin; CRP, C-reactive protein; IL-6, Interleukin-6; PCT, procalcitonin. In general, there was no statistically significant difference on the level of immune-inflammatory parameters between foreign and overseas Chinese travelers. However, overseas Chinese patients and local Chinese patients presented considerable differences on several hematological markers during hospitalization. In the initial 3 days, the average levels of C-reactive protein (CRP) and interleukin-6 (IL-6) in the local Chinese group were both approximately twice as high as those of overseas Chinese patients (p = 0.039 and p = 0.017, respectively, as shown in Figure 1A and B). The attenuated level of serum IL-6 remained significantly higher in local Chinese patients for over a week (4.46 ± 2.65 vs 2.74 ±1 .54 pg/mL, p = 0.043 for Tukey’s post-hoc test). Furthermore, in concomitance with the declines of pro-inflammatory cytokines during the following weeks of their hospitalization, there was an obviously sharp increase in the platelet count and a gradual decline of serum albumin (ALB) in local Chinese patients (Figure 1C and D), while the range of platelet counts was relatively stable over time in the overseas Chinese and foreign traveler groups. Subsequently, local Chinese patients recovered after an averaged 15.6 ± 2.8 days of hospital stay, while that was dramatically prolonged for approximately another 10 days in the groups of overseas Chinese and foreign travelers with an average of 26.4 ± 8.8 days (p <0.001) and 26.9 ± 7.0 days (p <0.001), respectively. Simultaneously, the group of foreign travelers exhibited with a significantly higher lymphocyte count of 3.52 ± 2.44 109/L on average in comparisons with both overseas Chinese (2.03 ± 0.59 109/L, p = 0.012) and local Chinese (1.75 ± 0.38 109/L, p = 0.002). On the other hand, the local Chinese patients had a relatively lower serum ALB with an average 40.91 ± 2.50 g/L compared with the foreign travelers (44.98 ± 2.49 g/L, p = 0.006), as well as the overseas Chinese (43.01 ± 2.23 g/L, p = 0.051).
Figure 1

Changes of laboratory parameters in the peri-hospitalization period. Comparisons on blood CRP (A) and IL-6 (B) indicated significantly higher inflammatory status in initial days of admission in local Chinese patients. Changes in ALB level (C) were identified with distinguishing levels among three groups. The local patients also presented with an obvious increase of the platelet count (D) and virus clearance rate (E), which were attenuated in overseas Chinese and foreign travelers. The independent two samples t-test is used between two groups and statistical tests are 2-tailed. A p value less than 0.05 is considered statistically significant. The asterisks indicate significant differences between the oversea Chinese and local Chinese patients (*p < 0.05, **p < 0.01, ***p < 0.001); the hash symbol indicates a significant difference between the foreign traveler and local Chinese groups (##p < 0.01, ###p < 0.001). Error bars: Mean ± SD.

Changes of laboratory parameters in the peri-hospitalization period. Comparisons on blood CRP (A) and IL-6 (B) indicated significantly higher inflammatory status in initial days of admission in local Chinese patients. Changes in ALB level (C) were identified with distinguishing levels among three groups. The local patients also presented with an obvious increase of the platelet count (D) and virus clearance rate (E), which were attenuated in overseas Chinese and foreign travelers. The independent two samples t-test is used between two groups and statistical tests are 2-tailed. A p value less than 0.05 is considered statistically significant. The asterisks indicate significant differences between the oversea Chinese and local Chinese patients (*p < 0.05, **p < 0.01, ***p < 0.001); the hash symbol indicates a significant difference between the foreign traveler and local Chinese groups (##p < 0.01, ###p < 0.001). Error bars: Mean ± SD. Results of detection of SARS-CoV-2 (Figure 1E) by real-time reverse transcription polymerase chain reaction (RT-qPCR) indicated that all the Chinese patients, including local and overseas ones, shared an equivalent capability of virus clearance initially. Subsequently, instead of the rapid rise in the proportion of patients with negative RT-PCR results in local Chinese group, overseas Chinese patients showed a suppression in the rate of virus clearance in the next week, followed by sharply rising up to a similar level of local Chinese patients contemporaneously. Remarkably, the virus negative rate in local Chinese patients was over 20% higher than that of the overseas group. These results corresponded with considerably prolonged days of hospital stay for overseas patients in comparison to local Chinese patients. In order to assess the prognostic value of initial inflammatory parameters, the Receiver Operator Characteristic (ROC) curve analysis of different cohorts (including incoming foreigners, overseas Chinese and local Chinese) were performed, showing that the area under the curve (AUC) for ALB level was 0.81 (95% CI: 0.72–0.90, p <0.001) in comparison between the total overseas patients and local Chinese (Figure 2). Furthermore, the AUC derived from the comparison between overseas and local Chinese was the highest with a value of 0.83 (95% CI: 0.74–0.92, p <0.001), whereas that between incoming foreign patients and the total Chinese patients was 0.49 (95% CI: 0.35–0.64, p = 0.95). These results suggested that ALB may be a favorable prognostic factor for community populations with geographic differences, especially overseas Chinese and local Chinese patients.
Figure 2

The Receiver Operator Characteristic (ROC) curves showing the performance of hematological parameters. The ROC curve analysis were performed on peripheral blood lymphocytes, platelets, CRP, IL-6 and ALB levels. The areas under the curve were calculated with the values of 0.57 (95% CI: 0.44–0.70, p = 0.294), 0.59 (95% CI: 0.46–0.72, p = 0.174), 0.33 (95% CI: 0.20–0.45, p = 0.007), 0.33 (95% CI: 0.21–0.45, p = 0.009), as well as 0.81 (95% CI: 0.72–0.90, p <0.001), respectively.

The Receiver Operator Characteristic (ROC) curves showing the performance of hematological parameters. The ROC curve analysis were performed on peripheral blood lymphocytes, platelets, CRP, IL-6 and ALB levels. The areas under the curve were calculated with the values of 0.57 (95% CI: 0.44–0.70, p = 0.294), 0.59 (95% CI: 0.46–0.72, p = 0.174), 0.33 (95% CI: 0.20–0.45, p = 0.007), 0.33 (95% CI: 0.21–0.45, p = 0.009), as well as 0.81 (95% CI: 0.72–0.90, p <0.001), respectively.

Discussion

Multiple reasons have been demonstrated with the contributions to the geospatial discrepancy on COVID-19 spread8–10 as well as the fatality.6,11 Here we showed that there existed dramatic differences in the inflammatory state and the clinical representations triggered by variable geographic distributions among local Chinese cases and overseas Chinese, as well as incoming foreign patients with SARS-CoV-2 infection. Mechanism studies have revealed that SARS-CoV-2 infection drives a unique and profound release of pro-inflammatory cytokines in the host,12,13 and thus the dysfunction of the intrinsic immune system may enhance the risk for severe SARS-CoV-2 infection.14 Except for the ethnicity-specific characteristics in the host genetic level, it has been implied that the geographical differences in the epidemiological prevalence and clinical representations of COVID-19 patients may be derived from viral genetic variants.15 The recent work showed that the different strains of SARS-CoV-2 virus, mutated on spike protein with a shift from D to G at position 614, possesses remarkable alterations in their current pathogenicity and transmissibility.16–18 In China, most samples are D614, while the viral samples of European and American cases are predominantly G614 variant, coordinately with a significant higher prevalence of chemosensory dysfunction than that of Asian patients.19 Some studies further demonstrated that the G614 strain was mainly associated with higher viral load and infectious titers,17 dispersing globally by travelers to different locations.20 Our current study revealed that incoming foreign patients and overseas Chinese patients exhibited lower levels of pro-inflammatory cytokines including IL-6 and CRP, juxtaposed to the attenuated viral elimination rate, as well as the prolonged hospital stay. Meanwhile local Chinese with confirmed COVID-19 experienced continuous improvements in virus removal capacity and a correspondingly shorter hospital stay. Therefore, our results confirmed the associations between diversity of clinical representations and geographic distribution of SARS-CoV-2 variants, and further indicated that the reduced viral clearance by G614 variant is probably associated with the attenuation of pro-inflammatory response in COVID-19 patients. On the other hand, we also looked at the factors associated with geographic communities in the global COVID-19 pandemic. Our results of ROC analysis showed that there was an association between serum ALB levels in COVID-19 patients and their geographic living environment. It suggested that a lower ALB level probably is an independent prognostic value for community populations from different geographic regions. Above all, our study provides clues on distinguishable distinctions of inflammatory state and clinical representations between overseas Chinese and local Chinese in the progression of COVID-19 infection, which contributes to evidence-based practice to combat the global spread of SARS-CoV-2 infection. This work underscores the need to identify distinguishably prognostic factors of geographical dissimilarity in COVID-19 patients.
  20 in total

1.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.

Authors:  Giacomo Grasselli; Alberto Zangrillo; Alberto Zanella; Massimo Antonelli; Luca Cabrini; Antonio Castelli; Danilo Cereda; Antonio Coluccello; Giuseppe Foti; Roberto Fumagalli; Giorgio Iotti; Nicola Latronico; Luca Lorini; Stefano Merler; Giuseppe Natalini; Alessandra Piatti; Marco Vito Ranieri; Anna Mara Scandroglio; Enrico Storti; Maurizio Cecconi; Antonio Pesenti
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

2.  Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.

Authors:  Erik Volz; Verity Hill; John T McCrone; Anna Price; David Jorgensen; Áine O'Toole; Joel Southgate; Robert Johnson; Ben Jackson; Fabricia F Nascimento; Sara M Rey; Samuel M Nicholls; Rachel M Colquhoun; Ana da Silva Filipe; James Shepherd; David J Pascall; Rajiv Shah; Natasha Jesudason; Kathy Li; Ruth Jarrett; Nicole Pacchiarini; Matthew Bull; Lily Geidelberg; Igor Siveroni; Ian Goodfellow; Nicholas J Loman; Oliver G Pybus; David L Robertson; Emma C Thomson; Andrew Rambaut; Thomas R Connor
Journal:  Cell       Date:  2020-11-19       Impact factor: 41.582

3.  Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects.

Authors:  Hanh T Nguyen; Shijian Zhang; Qian Wang; Saumya Anang; Jia Wang; Haitao Ding; John C Kappes; Joseph Sodroski
Journal:  J Virol       Date:  2020-12-11       Impact factor: 5.103

4.  The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.

Authors:  Qianqian Li; Jiajing Wu; Jianhui Nie; Li Zhang; Huan Hao; Shuo Liu; Chenyan Zhao; Qi Zhang; Huan Liu; Lingling Nie; Haiyang Qin; Meng Wang; Qiong Lu; Xiaoyu Li; Qiyu Sun; Junkai Liu; Linqi Zhang; Xuguang Li; Weijin Huang; Youchun Wang
Journal:  Cell       Date:  2020-07-17       Impact factor: 41.582

5.  Polymerase Chain Reaction Assays Reverted to Positive in 25 Discharged Patients With COVID-19.

Authors:  Jing Yuan; Shanglong Kou; Yanhua Liang; Jianfeng Zeng; Yanchao Pan; Lei Liu
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079

6.  COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Authors:  Georg Schett; Michael Sticherling; Markus F Neurath
Journal:  Nat Rev Immunol       Date:  2020-05       Impact factor: 53.106

7.  Effect of weather on COVID-19 spread in the US: A prediction model for India in 2020.

Authors:  Sonal Gupta; Gourav Singh Raghuwanshi; Arnab Chanda
Journal:  Sci Total Environ       Date:  2020-04-21       Impact factor: 7.963

8.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

9.  Geographic Differences in COVID-19 Cases, Deaths, and Incidence - United States, February 12-April 7, 2020.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-04-17       Impact factor: 17.586

Review 10.  Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.

Authors:  Ahmet Kursat Azkur; Mübeccel Akdis; Dilek Azkur; Milena Sokolowska; Willem van de Veen; Marie-Charlotte Brüggen; Liam O'Mahony; Yadong Gao; Kari Nadeau; Cezmi A Akdis
Journal:  Allergy       Date:  2020-07       Impact factor: 14.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.